“Weight Loss Miracle Drug” Linked to Increased Suicidal Tendencies?
- Why Lecanemab’s Adoption Faces an Uphill Battle in US?
- Yogurt and High LDL Cholesterol: Can You Still Enjoy It?
- WHO Releases Global Influenza Vaccine Market Study in 2024
- HIV Infections Linked to Unlicensed Spa’s Vampire Facial Treatments
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
“Weight Loss Miracle Drug” Linked to Increased Suicidal Tendencies?
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
“Weight Loss Miracle Drug” Linked to Increased Suicidal Tendencies? EU to Review Related Reports This Week
An agenda published on April 8th reveals that a committee of the European Medicines Agency (EMA) will convene this week to review reports linking GLP-1 class weight loss drugs to suicidal tendencies.
GLP-1 (glucagon-like peptide-1) is a type of intestinal hormone secreted by the body during food intake. Its functions include regulating insulin secretion, gastric emptying, and suppressing appetite.
The mechanism of GLP-1 class weight loss drugs is to suppress appetite in patients and slow down gastric emptying to achieve weight loss.
The most representative GLP-1 class drugs on the market are Wegovy and Ozempic, developed by Novo Nordisk. Wegovy and Ozempic contain the same active ingredient, semaglutide.
Trial data shows that Wegovy not only helps patients lose an average of 15% of their body weight (over approximately 68 weeks) but also reduces the incidence of heart attacks, strokes, or heart disease-related deaths by 20%.
However, in July last year, the Icelandic health regulator reported three cases of individuals having suicidal or self-harming thoughts after using Novo Nordisk’s drugs, involving Ozempic and another weight loss drug, Saxenda. EMA subsequently began investigating whether GLP-1 class weight loss drugs could increase suicidal tendencies.
In addition to Ozempic, Wegovy, and Saxenda, the drugs under investigation by EU regulators include Novo Nordisk’s Rybelsus, Victoza, and Xultophy. Regulators in several countries, including the United States, are investigating the link between GLP-1 class weight loss drugs and suicidal tendencies.
A preliminary investigation by the US Food and Drug Administration (FDA) in January found that the use of GLP-1 class weight loss drugs does not increase suicidal thoughts or lead to suicidal behavior.
However, the FDA also cautioned that, due to limited data, it cannot completely rule out the possibility of this risk and will continue to monitor the issue.
“Weight Loss Miracle Drug” Linked to Increased Suicidal Tendencies?
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
